Welcome to our dedicated page for AKSO HEALTH GROUP SEC filings (Ticker: AHG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is dedicated to the SEC filings of Akso Health Group (NASDAQ: AHG), a company that describes its business as spanning social e-commerce in China, medical device sales in China and the United States, radiotherapy oncology services, and online medical consultations. While specific filings are not listed here, investors typically review Akso Health Group’s reports to understand how these activities are reflected in its financial statements, risk disclosures, and corporate structure.
For a company like Akso Health Group, key filings on the SEC’s EDGAR system generally include annual reports on Form 20-F or Form 10-K, which provide a detailed overview of business segments such as healthcare equipment and product trading, medical devices, and oncology or online clinic services. Interim reports can offer updates on changes in operations, equity investments in online clinics, and developments in AI-powered healthcare initiatives like the integration of DeepSeek’s technology.
Investors may also be interested in current reports that describe material events, including notifications from Nasdaq regarding minimum bid price, stockholders’ equity, or filing timeliness, as referenced in the company’s press releases. In addition, insider transaction reports on Form 4, when available, can be used to monitor trading activity by directors and officers.
On Stock Titan, Akso Health Group’s SEC filings page is designed to surface these regulatory documents alongside AI-powered summaries that explain complex sections in plain language. As new filings are posted to EDGAR, they can be reflected here with concise explanations of key points, helping readers quickly identify disclosures related to medical devices, oncology services, online clinics, and AI healthcare initiatives associated with AHG.
Akso Health Group (AHG) presents a wide-ranging annual report describing a company transitioning from prior microlending activities into an "Internet+healthcare" and social e-commerce model while pursuing medical device sales, online consultations, community health stations and cancer therapy centers. The company reported higher sales and marketing spend of US$168,421 for the year ended March 31, 2024 versus US$6,661 the prior year driven by brand-building for new businesses, and a reduction in general and administrative expenses to US$8.6 million (down 44.7% from US$15.5 million) primarily due to lower provisions for uncollected receivables. The report discloses net income from discontinued operations of US$11.84 million and highlights significant operational and regulatory risk factors, including dependence on suppliers, client concentration, cybersecurity and data-protection obligations, heavy PRC regulatory oversight, potential HFCAA-related listing risks, lack of business insurance, and material uncertainties around approvals, licensing and cross-border capital flows.
FAQ
What is the current stock price of AKSO HEALTH GROUP (AHG)?
What is the market cap of AKSO HEALTH GROUP (AHG)?
